Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease

Experimental Neurology
C W ShultsDeborah Fontaine

Abstract

The safety and tolerability of high dosages of coenzyme Q10 were studied in 17 patients with Parkinson's disease (PD) in an open label study. The subjects received an escalating dosage of coenzyme Q10--1200, 1800, 2400, and 3000 mg/day with a stable dosage of vitamin E (alpha-tocopherol) 1200 IU/day. The plasma level of coenzyme Q10 was measured at each dosage. Thirteen of the subjects achieved the maximal dosage, and adverse events were typically considered to be unrelated to coenzyme Q10. The plasma level reached a plateau at the 2400 mg/day dosage and did not increase further at the 3000 mg/day dosage. Our data suggest that in future studies of coenzyme Q10 in PD, a dosage of 2400 mg/day (with vitamin E/alpha-tocopherol 1200 IU/day) is an appropriate highest dosage to be studied.

Associated Clinical Trials

Feb 6, 2008·Merit E. Cudkowicz, MD, Merit E. Cudkowicz, MD

References

Mar 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·R StockerB Frei
Feb 1, 1989·Journal of Clinical Pharmacology·M NakashimaN Morishita
Jan 1, 1994·Molecular Aspects of Medicine·M WeisS N Rasmussen
Jan 1, 1994·Molecular Aspects of Medicine·A ConstantinescuL Packer
Jan 1, 1997·Molecular Aspects of Medicine·R AllevaG P Littarru
Jul 23, 1999·BioFactors·A LassR S Sohal
Dec 17, 2003·Archives of Neurology·Clifford W Shults

❮ Previous
Next ❯

Citations

Dec 17, 2009·Applied Microbiology and Biotechnology·Marimuthu JeyaJung-Kul Lee
Apr 17, 2013·Journal of Neurology·Tom Foltynie, Joshua Kahan
Jul 11, 2006·Apoptosis : an International Journal on Programmed Cell Death·Jafar NaderiSiyaram Pandey
Jan 5, 2011·Cytotechnology·Yoshinobu KonnoShinji Hosoi
Nov 7, 2009·Current Treatment Options in Neurology·Sumit ParikhThe Mitochondrial Medicine Society
Aug 16, 2008·Archives of Pharmacal Research·Rengarajan BaskaranBong Kyu Yoo
Jan 31, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Douglas S Kerr
Oct 4, 2006·Annual Review of Pharmacology and Toxicology·Michael P Murphy, Robin A J Smith
Jan 24, 2012·International Journal of Toxicology·Padmaja Yerramilli-RaoMerit E Cudkowicz
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Brian S HilbushFloyd E Bloom
Dec 8, 2009·Neuropsychiatric Disease and Treatment·Meredith SpindlerClaire Henchcliffe
Aug 28, 2009·The Journal of Nutrition·Nathalie SumienMichael J Forster
Jan 15, 2014·Antioxidants & Redox Signaling·Raymond Chee-Seong SeetBarry Halliwell
Mar 5, 2013·Nutrition Reviews·Marnie PotgieterMichael S Pepper
Mar 23, 2006·Free Radical Research·Hemmi N Bhagavan, Raj K Chopra
Aug 31, 2006·Expert Opinion on Emerging Drugs·John C Morgan, Kapil D Sethi
Nov 29, 2007·Expert Opinion on Investigational Drugs·Edward C Stack, Robert J Ferrante
Apr 7, 2010·Expert Opinion on Investigational Drugs·Jose M VillalbaFrancisco J Alcain
Jun 7, 2005·Expert Opinion on Emerging Drugs·Hoon Ryu, Robert J Ferrante
May 15, 2015·Annual Review of Nutrition·Anita AyerRoland Stocker
Apr 10, 2013·Free Radical Biology & Medicine·Rajnish K Chaturvedi, M Flint Beal
Jan 8, 2015·Frontiers in Endocrinology·Janina Müller-Deile, Mario Schiffer
Mar 19, 2014·Frontiers in Aging Neuroscience·Stacey E SeidlJudith A Potashkin
Jun 21, 2005·Pharmacology & Therapeutics·Clifford W Shults
Jun 20, 2012·The Australian and New Zealand Journal of Psychiatry·Andrew A NierenbergDan V Iosifescu
Apr 20, 2006·The Annals of Pharmacotherapy·Cynthia A Weber, Michael E Ernst
Dec 7, 2007·Brain Research·L L Bambrick, G Fiskum
Apr 17, 2007·European Journal of Pharmacology·Hiroshi TsunekiToshiyasu Sasaoka
Aug 12, 2005·Neurorehabilitation and Neural Repair·W-L Kuan, R A Barker
May 19, 2011·Cephalalgia : an International Journal of Headache·Shalonda K SlaterAndrew D Hershey
Oct 14, 2017·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Beth A Taylor
Apr 30, 2013·International Journal of Molecular Sciences·Frank A D T G WagenerDitte M S Lundvig
Mar 27, 2018·Annals of Neurology·James M JoersGülin Öz
Sep 27, 2012·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·Paolo FogagnoloLuca Rossetti
May 18, 2012·The Cochrane Database of Systematic Reviews·Jia LiuYinyin Xia
Oct 5, 2010·Muscle & Nerve·Elisa I GloverMark A Tarnopolsky

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.